Abstract:Fractures occur in about half of older white women, and almost a third of older white men. However, 80% of the older individuals who have fractures do not meet the bone density definition of osteoporosis, suggesting that this definition is not an appropriate threshold for offering treatment. Fracture risk can be estimated based on clinical risk factors with or without bone density. A combination of calculated risk, fracture history, and bone density is used in treatment decisions. Medications available for reducing fracture risk act either to inhibit bone resorption or to promote bone formation. Romosozumab is unique in that it has both activities. Bisphosphonates are the most widely used interventions because of their efficacy, safety and low cost. Continuous use of oral bisphosphonates for >5 years increases the risk of atypical femoral fractures, so is usually punctuated with drug holidays of 6-24 months. Denosumab is a further potent antiresorptive agent given as six-monthly subcutaneous injections. It is comparable to the bisphosphonates in efficacy and safety but has a rapid offset of effect after discontinuation so must be followed by an alternative drug, usually a bisphosphonate. Teriparatide stimulates both bone formation and resorption, substantially increases spine density and reduces vertebral and non-vertebral fracture rates, though data for hip fractures are scant. Treatment is usually limited to 18-24 months, followed by transition to an anti-resorptive. Romosozumab is given as monthly subcutaneous injections for one year, followed by an anti-resorptive. This sequence prevents more fractures than anti-resorptive therapy alone. Because of cost, anabolic drugs are usually reserved for those at very high fracture risk. 25-hydroxyvitamin D levels should be maintained above 30 nmol/L, using supplements if sunlight exposure is limited. Calcium intake has little effect on bone density and fracture risk but should be maintained above 500 mg/day using dietary sources.

Fortnightly Review: Bone densitometry in clinical practice

Advances in bone imaging for osteoporosis

Novel Imaging Modalities in Osteoporosis Diagnosis and Risk Stratification

Osteoporosis epidemiology using international cohorts

Updated practice guideline for dual-energy X-ray absorptiometry (DXA)

Osteoporosis Screening and Fracture Risk Assessment Tool: Its Scope and Role in General Clinical Practice

Osteopenia: a key target for fracture prevention

Osteoporosis Imaging in the Geriatric Patient

[Advances in the diagnosis of osteoporosis]

Pathophysiology and treatment of osteoporosis: challenges for clinical practice in older people

Fracture prediction, imaging and screening in osteoporosis

Bone Densitometry: Current Status and Future Trends

Osteoporosis, Nutrition, and the Immune System

Clinical assessment of fracture risk and novel therapeutic strategies to combat osteoporosis

Osteoporosis management-current and future perspectives - A systemic review

The effectiveness of bone density measurement and associated treatments for prevention of fractures. An international collaborative review

Diagnosis and epidemiology of osteoporosis

European guidance for the diagnosis and management of osteoporosis in postmenopausal women

[Bone densitometry--the gold standard for diagnosis of osteoporosis].

Extensive Expertise in Endocrinology: Osteoporosis Management.

Opportunistic Use of CT Imaging for Osteoporosis Screening and Bone Density Assessment: A Qualitative Systematic Review